Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A.

AIDS. 2000 Mar 10;14(4):357-66.

PMID:
10770537
2.

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG.

AIDS. 2006 Jan 9;20(2):223-31.

PMID:
16511415
3.
4.

Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice.

Moreno A, Perez-Elías MJ, Casado JL, Muñoz V, Antela A, Dronda F, Navas E, Fortún J, Quereda C, Moreno S.

Antivir Ther. 2000 Dec;5(4):243-8.

PMID:
11142618
5.

[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].

Brunner J, Seybold U, Gunsenheimer-Bartmeyer B, Hamouda O, Bogner JR; ClinSurv-Studiengemeinschaft (gleichwertiger Beitrag)..

Dtsch Med Wochenschr. 2010 Jun;135(23):1166-70. doi: 10.1055/s-0030-1255124. Epub 2010 May 31. German.

PMID:
20514595
6.

Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.

Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.

AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1631-8.

PMID:
10606086
7.

Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.

Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC.

AIDS. 2007 Jul 31;21(12):1579-89.

8.

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM; ATHENA Project..

Arch Intern Med. 2001 Sep 10;161(16):1962-8.

PMID:
11525698
9.

Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia.

Ross L, Johnson M, DeMasi R, Liao Q, Graham N, Shaefer M, St Clair M.

AIDS. 2000 May 5;14(7):813-9.

PMID:
10839589
10.

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.

Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M.

AIDS. 2002 Jul 26;16(11):1511-9.

PMID:
12131189
11.

Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.

Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F, Rouzioux C, Blanche S.

J Med Virol. 2007 Sep;79(9):1261-9.

PMID:
17607781
13.

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group..

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36.

PMID:
11464141
14.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
15.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
16.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team..

JAMA. 2002 Jul 10;288(2):169-80.

PMID:
12095381
17.

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.

Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C; Aproco Study Group..

AIDS. 2002 Jan 4;16(1):21-9.

PMID:
11741159
18.

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.

Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, Fleury H, Garraffo R, Chêne G, Raffi F, Brun-Vézinet F; APROCO/COPILOTE Study Group..

J Clin Virol. 2005 May;33(1):75-8.

PMID:
15797369
19.

A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.

Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.

HIV Med. 2005 Sep;6(5):353-9. Erratum in: HIV Med. 2005 Nov;6(6):426.

20.

Supplemental Content

Support Center